MEDI 500

Drug Profile

MEDI 500

Alternative Names: Anti-TCR-alphabeta monoclonal antibody T10B9; G 022; T-10B9; T10B9 monoclonal antibody; T10B9.1A31; T12A10

Latest Information Update: 21 Jun 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Kentucky Chandler Medical Center
  • Class Monoclonal antibodies
  • Mechanism of Action Immunosuppressants; T-cell receptor antigen alpha-beta antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Graft-versus-host disease; Heart transplant rejection; Liver transplant rejection; Renal transplant rejection

Most Recent Events

  • 19 Jun 2007 MedImmune has been acquired by AstraZeneca
  • 12 Mar 2004 It appears that BioTransplant has ceased operations
  • 28 Nov 2003 BioTransplant expects to file with the Bankruptcy Court in the coming weeks
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top